PRKDC and cancer: Since cancer-IgG is specifically secreted by cancer cells and is capable of promoting the phosphorylation of DNA-PKcs, targeted pharmacological inhibition of cancer-IgG holds the promise to significantly circumvent the problematic normal tissue toxicities of traditional DNA-PKIs while providing similar radiosensitizing effects.